Bristol-Myers Squibb Co. (BMY) announced that it successfully completed the tender offer by the company through its wholly owned subsidiary, B&R Acquisition Co., for all of the outstanding shares of common stock of Amylin Pharmaceuticals, Inc. (AMLN) at a purchase price of $31 per share.
Bristol-Myers Squibb stated that as of the expiration of the offer on August 8, 140.55 million shares of common stock of Amylin were validly tendered and not withdrawn in the tender offer.
As part of the successful completion of the tender offer, Bristol-Myers Squibb exercised its right granted under the merger agreement with Amylin pursuant to which the tender offer was made to purchase additional shares from Amylin which would allow Bristol-Myers Squibb to complete the merger without stockholder approval.
For comments and feedback: editorial@rttnews.com